Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms GW3965-PEG3-POM |
Target |
Mechanism LXR degraders(Liver X receptor degraders) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC52H53ClF3N5O8 |
InChIKeyCTXRTQMAQXZXKV-UHFFFAOYSA-N |
CAS Registry- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus | Preclinical | JP | 26 May 2021 | |
Diabetes Mellitus | Preclinical | JP | 26 May 2021 | |
Hypercholesterolemia | Preclinical | JP | 26 May 2021 | |
Hypercholesterolemia | Preclinical | JP | 26 May 2021 |